• Home
  • Ministers
    • The Hon Greg Hunt MPMinister for Health
    • Senator the Hon Bridget McKenzieMinister for Regional ServicesMinister for SportMinister for Local Government and Decentralisation
    • The Hon Ken Wyatt AM MPMinister for Senior Australians and Aged CareMinister for Indigenous Health
    • Current Issues
  • For Consumers
    • Aboriginal and Torres Strait Islander Health
    • Conditions and Diseases
    • Education and Prevention
    • Ethical Issues
    • Gene Technology
    • Health products and medicines
    • Public and private healthcare
    • Medicare
    • Mental Health
    • National Men's and Women's Health
    • Palliative Care
    • Pharmacy
    • Primary Care
    • Regulation and Red Tape Reduction
    • Rural and Regional Health
    • Services
    • Healthier Medicare
    • Travel Health Information
  • For Health Professionals
    • Aboriginal and Torres Strait Islander Health
    • Conditions and Diseases
    • Education and Prevention
    • eHealth
    • Ethical Issues
    • Gene Technology
    • Health Provider Compliance
    • Health products and medicines
    • Health Thesaurus
    • Health Workforce
    • Public and private healthcare
    • Medicare
    • National Men's and Women's Health
    • Palliative Care
    • Regulation and Red Tape Reduction
    • Rural and Regional Health
    • Services
    • Healthier Medicare
    • Travel Health Information
  • About Us
    • Our Organisation
    • Contact us
    • Annual Reports
    • Budget
    • Tenders and Grants
    • Flexible Funds - program consolidation
    • Legislation & Policy
    • Freedom of Information Disclosure Log
    • Public Interest Disclosure
    • Departmental Records
    • Consultations
    • Social Media
    • Health Jobs
    • Calendar of Events
    • History
  • Media Centre
    • Australian Health Ministers' Conference
    • Council of Australian Governments (COAG)
    • Departmental media releases and speeches
    • Health Warnings
    • Media release subscriptions
    • Ministerial Media Releases, transcripts and speeches
    • National Health and Medical Research Council (NHMRC) media releases
    • Therapeutic Goods Administration (TGA) media releases
    • Government responses to enquiries
  • Programs & Campaigns
    • Agreements
    • Awards
    • eHealth
    • Programs & Initiatives
    • Campaign Certification Statements
  • Resources
    • Publications
    • Research & Statistics
    • CurrentIssues
  • Ageing & Aged Care
  • You are here:
  • Home /
  • For Consumers /
  • Education and Prevention /
  • Illicit Drugs /

Comorbid mental disorders and substance use disorders: epidemiology, prevention and treatment

Chapter 7: Comorbidity: why does it matter?

Page last updated: 2003

Leonie Manns

A consumer perspective

Conclusions

References

  • previous page
  • next page
Listen
  • Table of contents
  • Chapter 1: Responding to comorbid mental disorders and substance use disorders
    • How common is comorbidity?
    • How would you prevent and treat comorbidity?
    • What are the implications for service delivery?
    • References
  • Introduction to the chapters in the monograph
  • Chapter 2: What is comorbidity and why does it occur?
    • Introduction
    • Definitions
    • Why study comorbidity?
    • The importance of general population research on comorbidity
    • General studies of comorbidity
    • Explanations of comorbidity
    • Conclusions
    • References
  • Chapter 3: How common is comorbidity?
    • Introduction
    • International studies
    • The Australian National Survey of Mental Health and Wellbeing (NSMHWB)
    • What are the most disabling comorbidities?
    • Conclusions
    • References
  • Chapter 4: Comorbidity and early intervention/prevention
    • Introduction: Aims and definitions
    • Risk factors for individual disorders
    • Comorbidity
    • Windows of opportunity: outcome studies in the prevention of internalising disorders and externalising disorders
    • Intervention and community health issues in the prevention of internalising disorders, externalising disorders and substance use disorders
    • Conclusions
    • References
  • Chapter 5: Management of comorbidity
    • Introduction
    • Implications of comorbidity for management
    • Assessment of comorbidity
    • Interventions of comorbidity
    • Conclusions
    • References
  • Chapter 6: Comorbidity and delivery of services
    • Introduction
    • Impact of comorbidity on the course of illness and use of services
    • Preventative programs
    • Treatment services
    • Conclusions
    • References
  • Chapter 7: Comorbidity: why does it matter?
    • A consumer perspective
    • Conclusions
    • References
  • Chapter 8: Conclusion

Popular

    • Feedback
    Provide feedbackIf you would like a response please complete our enquiries form.


    Comments will be used to improve web content and will not be responded to.

    Real person check

    This form uses a CAPTCHA to ensure that it is submitted by a person, instead of a machine or automated software.


    Privacy statement

    Your feedback has been submitted

    Thank you for taking the time to provide feedback. It will be used to make improvements to this website.